SCHEMBL4236991

SCHEMBL4236991

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N)cc2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.53
▸ MET P08581 2/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.46
▸ TAS1R1 Q7RTX1 1/20 0.46
▸ PNLIP P16233 1/20 0.44
▸ EPHX2 P34913 4/20 0.42
▸ RAF1 P04049 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ KDR P35968 3/20 0.40
▸ BRAF P15056 1/20 0.40
▸ PDGFRA P16234 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4228260 0.87 PKM (0.54) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4238927 0.87 PKM (0.54) PKMTAS1R3TAS1R1PNLIPCYP2C9
SCHEMBL4229305 0.86 PKM (0.60) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL4240850 0.86 PKM (0.53) PKMTAS1R3TAS1R1PNLIPMAPT
SCHEMBL4228811 0.86 PKM (0.60) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL4234115 0.86 PKM (0.50) PKMTAS1R3TAS1R1EPHX2RAF1
SCHEMBL4236665 0.85 PKM (0.52) PKMTAS1R3TAS1R1CYP2C9CYP2C19
Ammonia Solution, Strong SCHEMBL4235457 0.85 PKM (0.58) PKMTAS1R3TAS1R1ALDH1A1MEN1
SCHEMBL5149411 0.85 PKM (0.52) PKMTAS1R3TAS1R1PNLIPCYP2C9
SCHEMBL4238162 0.85 PKM (0.52) PKMTAS1R3TAS1R1PNLIPCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
WO-2007071840-A2 COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF CEREP (FR) 2007-06-28 — — WO disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MET 3062/4885TAS1R3 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback